Erythropoietic agents in anaemic patients with cancer: A retrospective observational survey of epoetin α, epoetin β and darbepoetin α use in routine clinical practice

Oncology Reports

Volumn 14, Issue 4, 2005, Pages 1037-1044

  Pujade Lauraine, Eric ^a   Richard, Alain J ^b   Sapede, Claudine ^c   Hayward, Colin ^c  

^a HÔTEL DIEU   (France)

^b GECEM   (France)

^c F HOFFMANN LA ROCHE LTD   (Switzerland)

Author keywords

Cancer; Darbepoetin ; Epoetin ; Epoetin ; Retrospective study

Indexed keywords

ANTIANEMIC AGENT; DRUG DERIVATIVE; ERYTHROPOIETIN; HEMOGLOBIN; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; RECOMBINANT ERYTHROPOIETIN;

ADULT; AGED; ANEMIA; ARTICLE; BLOOD TRANSFUSION; CLINICAL TRIAL; DRUG EFFECT; ERYTHROPOIESIS; FEMALE; HUMAN; MALE; MIDDLE AGED; MULTICENTER STUDY; NEOPLASM; RETROSPECTIVE STUDY; TIME; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; ANEMIA; BLOOD TRANSFUSION; EPOETIN ALFA; ERYTHROPOIESIS; ERYTHROPOIETIN; ERYTHROPOIETIN, RECOMBINANT; FEMALE; HEMATINICS; HEMOGLOBINS; HUMANS; MALE; MIDDLE AGED; NEOPLASMS; RETROSPECTIVE STUDIES; TIME FACTORS; TREATMENT OUTCOME;

EID: 33644830985     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.14.4.1037     Document Type: Article

References (34)

1. Groopman JE and Itri LM: Chemotherapy-induced anemia in adults: incidence and treatment. J Natl Cancer Inst 91: 1616-1634, 1999. (Pubitemid 29479929)
2. Knight K, Wadw S and Balducci L: Prevalence and outcomes of anemia in cancer: a systematic review of the literature. Am J Med 116: 11S-26S, 2004.
3. Cella D: Factors influencing quality of life in cancer patients: anemia and fatigue. Semin Oncol 25 (Suppl. 7): 43-46, 1998.
4. Glaser CM, Millesi W, Kornek GV, et al: Impact of hemoglobin level and use of recombinant erythropoietin on efficacy of preoperative chemoradiation therapy for squamous cell carcinoma of the oral cavity and oropharynx. Int J Radiation Oncol Biol Phys 50: 705-715, 2001. (Pubitemid 32519598)
5. Van Belle S J-P and Cocquyt V: Impact of haemoglobin levels on the outcome of cancers treated with chemotherapy. Critl Rev Oncol Hematol 47: 1-11, 2003. (Pubitemid 36802321)
6. Caro J, Salas M, Ward A and Goss G: Anemia as an independent prognostic factor for survival in patients with cancer. Cancer 91: 2214-2221, 2001. (Pubitemid 32552805)
7. Cazzola M, Beguin Y, Kloczko J, Spicka I and Coiffier B: Once-weekly epoetin beta is highly effective in treating anaemic patients with lymphoproliferative malignancy and defective endogenous erythropoietin production. Br J Haematol 122: 386-393, 2003. (Pubitemid 36951622)
8. Gabrilove JL, Cleeland CS, Livingston RB, Sarokhan B, Winer E and Einhorn LH: Clinical evaluation of once-weekly dosing of epoetin alfa in chemotherapy patients: improvements in hemoglobin and quality of life are similar to three-times-weekly dosing. J Clin Oncol 19: 2875-2882, 2001. (Pubitemid 32538197)
9. Oberhoff C, Neri B, Amadori D, et al: Recombinant human erythropoietin in the treatment of chemotherapy-induced anemia and prevention of transfusion requirement associated with solid tumors: a randomized, controlled study. Ann Oncol 9: 255-260, 1998. (Pubitemid 28186794)
10. Österborg A, Brandberg Y, Molostova V, et al: Randomized, double-blind, placebo-controlled trial of recombinant human erythropoietin, epoetin beta, in hematologic malignancies. J Clin Oncol 20: 2486-2494, 2002. (Pubitemid 34525734)
11. Eprex® - Summary of Product Characteristics. Janssen-Cilag ltd., UK. Issued July 2003.
12. NeoRecormon® - Summary of Product Characteristics. Roche Registration ltd., UK. Issued March 2004.
13. Glaspy JA, Jadeja JS, Justice G, et al: Darbepoetin alfa given every 1 or 2 weeks alleviates anaemia associated with cancer chemotherapy. Br J Cancer 87: 268-276, 2002.
14. Hedenus M, Adriansson M, San Miguel J, et al: Efficacy and safety of darbepoetin alfa in anaemic patients with lymphoproliferative malignancies: a randomized, double-blind, placebo-controlled study. Br J Haematol 122: 394-403, 2003. (Pubitemid 36951623)
15. Kotasek D, Steger G, Faught W, et al: Darbepoetin alfa administered every 3 weeks alleviates anaemia in patients with solid tumours receiving chemotherapy; results of a double-blind, placebo-controlled, randomised study. Eur J Cancer 39: 2026-2034, 2003. (Pubitemid 37297759)
16. Aranesp® - Summary of Product Characteristics. Amgen Europe BV, The Netherlands. Issued September 2004.
17. Egrie JC and Browne JK: Development and characterization of novel erythropoiesis stimulating protein (NESP). Br J Cancer 84 (Suppl. 1): 3-10, 2001. (Pubitemid 32453429)
18. Morreale A, Plowman B, De Lattre M, Boggie D and Schaefer M: Clinical and economic comparison of epoetin alfa and darbepoetin alfa. Curr Med Res Opin 20: 381-395, 2004. (Pubitemid 38339178)
19. Aljama P, Bommer J, Canaud B, et al: Practical guidelines for the use of NESP in treating renal anaemia. Nephrol Dial Transplant 16 (Suppl. 3): 22-28, 2001. (Pubitemid 32591161)
20. Deray G: Once-weekly erythropoietic therapy: is there a difference between the available preparations? Nephrol Dial Transplant 18: 2455-2456, 2003.
21. Federal Register part III. Department of Health and Human Services. Centers for Medicare and Medicaid Services. 42 CFR Parts 410 and 419 Medicare Program; changes to the Hospital Outpatient Prospective Payment System and calendar year 2004 payment rates; final rule. November 7, 68 (216): 63455-63458, 2003.
22. Barnett AI and Crémieux PY: Dose conversion from epoetin alfa to darbepoetin alfa for patients with chronic kidney disease receiving hemodialysis. Pharmacotherapy 23: 690-694, 2003. (Pubitemid 36539052)
23. Vansteenkiste J, Pirker R, Massuti B, et al: Double-blind, placebo-controlled, randomized phase III trial of darbepoetin alfa in lung cancer patients receiving chemotherapy. J Natl Cancer Inst 94: 1211-1220, 2002. (Pubitemid 34993871)
24. Coiffier B: Epoetin once weekly in anaemic patients with cancer. Br J Haematol 125: 100-101, 2004.
25. Patton J, Reeves T and Wallace J: Effectiveness of darbepoetin alfa versus epoetin alfa in patients with chemotherapy-induced anemia treated in clinical practice. Oncologist 9: 451-458, 2004. (Pubitemid 39014556)
26. Schwartzberg L, Shiffman R, Tomita D, Stolshek B, Rossi G and Adamson R: A multicenter retrospective cohort study of practice patterns and clinical outcomes of the use of darbepoetin alfa and epoetin alfa for chemotherapy-induced anemia. Clin Ther 25: 2781-2796, 2003. (Pubitemid 37510589)
27. Bokemeyer C, Aapro MS, Courdi A, et al: EORTC guidelines for the use of erythropoietic proteins in anaemic patients with cancer. Eur J Cancer 40: 2201-2216, 2004. (Pubitemid 39348870)
28. Glaspy J, Bukowski R, Steinberg D, Taylor C, Tchekmedyian S and Vadhan-Raj S: Impact of therapy with epoetin alfa on clinical outcomes in patients with non-myeloid malignancies during cancer chemotherapy in community oncology practice. J Clin Oncol 15: 1218-1234, 1997. (Pubitemid 27106310)
29. Demetri GD, Kris M, Wade J, Degos L and Cella D: Quality-of-life benefit in chemotherapy patients treated with epoetin alfa is independent of disease response or tumor type: results from a prospective community oncology study. J Clin Oncol 16: 3412-3425, 1998. (Pubitemid 28481641)
30. Vadhan-Raj S, Mirtsching B, Charu V, Terry D, Rossi G, Tomita D and McGuire WP: Assessment of hematologic effects and fatigue in cancer patients with chemotherapy-induced anemia given darbepoetin alfa every two weeks. J Support Oncol 1: 131-138, 2003.
31. Witzig TE, Silberstein PT, Loprinzi CL, et al: Phase III, randomized, double-blind study of epoetin alfa versus placebo in anemic patients with cancer undergoing chemotherapy. J Clin Oncol 23: 2006-2617, 2005.
32. Halstenson CE, Macres M, Katz SA, et al: Comparative pharmacokinetics and pharmacodynamics of epoetin alfa and epoetin beta. Clin Pharmacol Ther 50: 702-712, 1991.
33. Storring PL, Tiplady RJ, Gaines Das RE, Stenning BE, Lamikanra A, Rafferty B and Lee J: Epoetin alfa and beta differ in their erythropoietin isoform compositions and biological properties. Br J Haematol 100: 79-89, 1998. (Pubitemid 28051844)
34. Hedenus M, Hansen S, Taylor K, et al: Randomized, dose-finding study of darbepoetin alfa in anaemic patients with lymphoproliferative malignancies. Br J Haematol 119: 79-86, 2002. (Pubitemid 35176501)